image
Healthcare - Medical - Devices - NASDAQ - US
$ 13.93
-1.23 %
$ 394 M
Market Cap
-16.88
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one CLPT stock under the worst case scenario is HIDDEN Compared to the current market price of 13.9 USD, ClearPoint Neuro, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one CLPT stock under the base case scenario is HIDDEN Compared to the current market price of 13.9 USD, ClearPoint Neuro, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one CLPT stock under the best case scenario is HIDDEN Compared to the current market price of 13.9 USD, ClearPoint Neuro, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CLPT

image
$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
31.4 M REVENUE
31.04%
-19.7 M OPERATING INCOME
12.03%
-18.9 M NET INCOME
14.37%
-8.95 M OPERATING CASH FLOW
34.77%
-275 K INVESTING CASH FLOW
-3.07%
6.19 M FINANCING CASH FLOW
1990.88%
8.48 M REVENUE
9.19%
-6.16 M OPERATING INCOME
-9.98%
-6.03 M NET INCOME
-11.88%
-6.17 M OPERATING CASH FLOW
-396.54%
-183 K INVESTING CASH FLOW
30.42%
-1.36 M FINANCING CASH FLOW
-3681.08%
Balance Sheet ClearPoint Neuro, Inc.
image
Current Assets 33.4 M
Cash & Short-Term Investments 20.1 M
Receivables 4.71 M
Other Current Assets 8.55 M
Non-Current Assets 5.83 M
Long-Term Investments 0
PP&E 5.09 M
Other Non-Current Assets 735 K
51.30 %12.03 %21.81 %12.99 %Total Assets$39.2m
Current Liabilities 10.4 M
Accounts Payable 1.34 M
Short-Term Debt 557 K
Other Current Liabilities 8.46 M
Non-Current Liabilities 3.45 M
Long-Term Debt 6.02 M
Other Non-Current Liabilities -2.58 M
9.71 %4.04 %61.28 %43.64 %Total Liabilities$13.8m
EFFICIENCY
Earnings Waterfall ClearPoint Neuro, Inc.
image
Revenue 31.4 M
Cost Of Revenue 12.3 M
Gross Profit 19.1 M
Operating Expenses 38.9 M
Operating Income -19.7 M
Other Expenses -832 K
Net Income -18.9 M
40m40m30m30m20m20m10m10m00(10m)(10m)(20m)(20m)31m(12m)19m(39m)(20m)832k(19m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
60.92% GROSS MARGIN
60.92%
-62.91% OPERATING MARGIN
-62.91%
-60.25% NET MARGIN
-60.25%
-74.50% ROE
-74.50%
-48.26% ROA
-48.26%
-67.18% ROIC
-67.18%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis ClearPoint Neuro, Inc.
image
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)(18m)(18m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -18.9 M
Depreciation & Amortization 1.9 M
Capital Expenditures -275 K
Stock-Based Compensation 6.91 M
Change in Working Capital 1.4 M
Others -1.49 M
Free Cash Flow -9.22 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets ClearPoint Neuro, Inc.
image
Wall Street analysts predict an average 1-year price target for CLPT of $19.8 , with forecasts ranging from a low of $9 to a high of $30 .
CLPT Lowest Price Target Wall Street Target
9 USD -35.39%
CLPT Average Price Target Wall Street Target
19.8 USD 42.14%
CLPT Highest Price Target Wall Street Target
30 USD 115.36%
Price
Max Price Target
Min Price Target
Average Price Target
3030252520201515101055Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership ClearPoint Neuro, Inc.
image
Sold
0-3 MONTHS
128 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
I Missed The Quantum Rally - I Won't Miss The Next One Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature superconductors. Monitor each sector's stocks poised to soar if a major tech player announces a breakthrough. seekingalpha.com - 1 month ago
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS. zacks.com - 1 month ago
ClearPoint Neuro, Inc. (CLPT) Q1 2025 Earnings Call Transcript ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Joseph Burnett - President and Chief Executive Officer Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Frank Takkinen - Lake Street Capital Markets Anderson Schock - B. Riley Securities Operator Greetings and welcome to ClearPoint Neuro, Inc. First Quarter 2025 Financial Results Conference Call. seekingalpha.com - 1 month ago
ClearPoint Neuro, Inc. (CLPT) Reports Q1 Loss, Tops Revenue Estimates ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.16 per share a year ago. zacks.com - 1 month ago
ClearPoint Neuro Reports First Quarter 2025 Results Record Revenue Highlighted by 70% Growth in Single-Use Navigation and Therapy Products SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 13, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2025. First Quarter Highlights Reported record quarterly revenue of $8.5 million, an 11% year-over-year increase compared with the first quarter of 2024; Grew total consumable product revenue by $2.6 million year-over-year, or 104%, including biologics and drug delivery cannulas, SmartFrame® Family Navigation devices, and ClearPoint PRISM® Laser Therapy Applicators; Received FDA Clearance for the ClearPoint 3.0 Software which includes both operating room navigation capability and enhanced laser therapy features. accessnewswire.com - 1 month ago
Wall Street Analysts Believe ClearPoint Neuro (CLPT) Could Rally 102.86%: Here's is How to Trade The average of price targets set by Wall Street analysts indicates a potential upside of 102.9% in ClearPoint Neuro (CLPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com - 1 month ago
ClearPoint Neuro Announces Investment of up to $110 Million by Oberland Capital with $33.5 Million Funded at Closing SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 12, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it has entered into a note financing arrangement with Oberland Capital Management LLC ("Oberland Capital") of up to $105 Million, with $30.0 million of gross proceeds funded at closing. Additional note financing will be provided to the Company by Oberland Capital under the following terms: An additional $25.0 million at the option of the Company any time prior to December 31, 2026; and An additional $50.0 million at the option of the Company and Oberland Capital any time prior to December 31, 2026. accessnewswire.com - 1 month ago
ClearPoint Neuro: Fundamentals Continue To Strengthen ClearPoint continues to make progress in relation to its LITT and operating room expansion efforts. More importantly, ClearPoint's partners continue to provide positive news in relation to their therapeutic candidates. It will take time for these tailwinds to impact ClearPoint's financials, but 2026/2027 onwards should see a step change in performance. seekingalpha.com - 1 month ago
ClearPoint Neuro to Announce First Quarter 2025 Results May 13, 2025 SOLANA BEACH, CA / ACCESS Newswire / April 25, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2025 first quarter on Tuesday, May 13th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2025 first quarter on Tuesday, May 13th, at 4:30 p.m. accessnewswire.com - 1 month ago
ClearPoint Neuro: Drug Delivery Prospects Continue To Strengthen ClearPoint's Q4 results were soft, although lumpy growth should be expected given the nature of ClearPoint's business. Neurosurgery growth remains robust, and the expansion of preclinical and clinical services should provide the drug delivery business with a boost within the next 18 months. ClearPoint also continues to control its cash burn, despite continuing to make investments in future growth. seekingalpha.com - 3 months ago
ClearPoint Neuro, Inc. (CLPT) Q4 2024 Earnings Call Transcript ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Anderson Schock - B. Riley Securities Operator Greetings. seekingalpha.com - 3 months ago
ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Misses Revenue Estimates ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.19 per share a year ago. zacks.com - 3 months ago
8. Profile Summary

ClearPoint Neuro, Inc. CLPT

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 394 M
Dividend Yield 0.00%
Description ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Contact 120 S. Sierra Avenue, Solana Beach, CA, 92075 https://www.clearpointneuro.com
IPO Date May 22, 2012
Employees 115
Officers Ms. Ellisa Cholapranee J.D. General Counsel & Secretary Mr. Mazin Sabra Chief Operating Officer Mr. Danilo D'Alessandro Chief Financial Officer Mr. Jeremy L. Stigall Chief Business Officer Mr. Joseph Michael Burnett President, Chief Executive Officer & Director